Plain-English translation of NCT06084117 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
When COPD gets severely worse, it can be life-threatening and make it hard for your body to get enough oxygen and remove carbon dioxide. This trial is testing whether High Flow Nasal Oxygen (HFNO)—a newer breathing support method that delivers warm, humid oxygen through soft nose tubes—works as well as the current standard treatment called Non-Invasive Ventilation (NIV), which uses a face mask or helmet to help you breathe. The researchers want to see if HFNO is easier to tolerate and requires less nursing care while being just as effective.
While NIV is the current standard treatment for severe COPD flare-ups, many patients can't tolerate it because it's uncomfortable, causes agitation, or doesn't sync well with their breathing. HFNO might be a gentler option that patients find easier to use, but researchers need to test whether it works equally well and is practical to use in hospitals.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you'll be randomly assigned to receive either High Flow Nasal Oxygen or standard Non-Invasive Ventilation as your first treatment for your COPD flare-up. You'll stay in the hospital on a monitored ward or ICU where doctors and nurses will regularly check your blood oxygen levels, give you steroids and bronchodilators as usual, and adjust your oxygen settings to keep you comfortable and safe. The main focus is testing whether this new breathing method works well and is easier for patients to tolerate than the current standard.
AI-generated summary from trial data · Jul 17, 2026 · Not medical advice
Netherlands
Sponsor
Franciscus Gasthuis
Collaborators
Reinier de Graaf Groep, Haga Medisch Centrum
Enrollment target
~40 participants
Started
May 2024
Primary completion
September 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
40 Years and older
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dorien Kiers, MD, PhD
Franciscus Gasthuis & Vlietland
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.